About Accipiter Biosciences
Accipiter Biosciences is a private company based in Seattle, Washington, incorporated in 2023 in Delaware. It has reported $24,741,270 raised in three offerings on Form D since May 2023. Its chief executive is Matthew Bick.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Jul 21, 2026 | Jul 28, 2026 | $10,492,778fully sold | 9 | $1.1M | EquityRule 506(b) | Form D ↗ |
| May 17, 2024 | May 28, 2024amended Sep 24, 2025 | $13,598,492of $13.6M target | 15 | $906K | EquityRule 506(b) | Form D/A ↗1 earlier filing |
| Apr 19, 2023 | May 2, 2023 | $650,000of $1.0M target | 6 | $108K | Options, Securities on exerciseRule 506(b) | Form D ↗ |
| Total, three offerings | $24,741,270 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Accipiter Biosciences's Form D filed Jul 28, 2026.
Earlier filings also listed Jiaping Gu (director, last listed Sep 2025), Heather Gorham (director, last listed Sep 2025), William Arthur (chief executive officer and director, last listed May 2023) and Hector Arano (executive officer, director and promoter, last listed May 2023).